MacroGenics Q1 2022 Earnings Report
Key Takeaways
MacroGenics reported first quarter 2022 financial results, with total revenue of $11.1 million, including $3.6 million in MARGENZA sales. The company's net loss was $66.4 million. They plan to start Phase 2/3 prostate cancer study with MGC018 by year-end and initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors.
Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end.
Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors.
Targeting mid-2022 start of Phase 1 study of MGD024 in hematologic malignancies.
FDA accepted the Biologics License Application (BLA) for teplizumab for the delay of clinical T1D in at-risk individuals.
MacroGenics
MacroGenics
MacroGenics Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income